Healthcare / BiotechnologyOslo
$0.66
-0.21 (-24.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-72.3M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$74M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-283.2%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-87.0M · FCF $-72.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-87.0M | $-87.0M | $-52.3M | $-48.3M | $-40.1M |
| EBITDA | $-83.2M | $-83.2M | $-49.8M | $-46.2M | $-38.5M |
| EPS | — | — | — | -1.51 | -1.34 |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 |
| Current Ratio | 1.65 | 1.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-72.3M | $-72.3M | $-82.1M | $-47.4M | $-34.1M |
| Returns | |||||
| ROE | -283.2% | -283.2% | -45.3% | -107.3% | -61.6% |
| Valuation | |||||
| P/B | 1.36 | 1.36 | 2.07 | 8.54 | 5.44 |
| Growth & Yield | |||||
| EPS Growth | — | — | — | -12.7% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-76.3%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
-76.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.